Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY121
MIFTS: 59

Thyroid Gland Anaplastic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards integrated aliases for Thyroid Gland Anaplastic Carcinoma:

Name: Thyroid Gland Anaplastic Carcinoma 12
Anaplastic Thyroid Carcinoma 12 54 60 6
Anaplastic Thyroid Cancer 77 54
Thyroid Carcinoma, Anaplastic 54
Thyroid Carcinoma Anaplastic 56
Thyroid Cancer, Anaplastic 54

Characteristics:

Orphanet epidemiological data:

60
anaplastic thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare endocrine diseases


Sources

Summaries for Thyroid Gland Anaplastic Carcinoma

About this section
NIH Rare Diseases : 54 Anaplastic thyroid cancer(ATC) accounts for less than 2% of all thyroid cancers and is the most aggressive type of thyroid cancer. Most cases of anaplastic thyroid cancer are diagnosed in the sixth to seventh decade of life. Women are more likely to be affected than men. ATC generally occurs in individuals with a history of goiter or thyroid cancer. A history of head and neck radiation or exposure to radioactive materials may also increase the risk for ATC. Patients with ATC generally present with a rapidly-growing neck mass which may cause trouble swallowing (dysphagia), coughing, neck pain, and trouble breathing (dyspnea).Metastasis is present in more than half of individuals at the time of diagnosis. Patients with metastases may also present with bone pain, lymph node enlargement, weakness, and neurological deficits. Treatment of ATC is mostly palliative.

MalaCards based summary : Thyroid Gland Anaplastic Carcinoma, also known as anaplastic thyroid carcinoma, is related to papillary thyroid microcarcinoma and graves disease 1. An important gene associated with Thyroid Gland Anaplastic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and endothelial, and related phenotypes are anaplastic thyroid carcinoma and broad neck

Disease Ontology : 12 A thyroid carcinoma that is composed of undifferentiated cells.

Wikipedia : 77 Anaplastic thyroid cancer is a form of thyroid cancer which has a very poor prognosis due to its... more...

Sources

Related Diseases for Thyroid Gland Anaplastic Carcinoma

About this section

Diseases related to Thyroid Gland Anaplastic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Related Disease Score Top Affiliating Genes
1 papillary thyroid microcarcinoma 30.0 BRAF NKX2-1 TG
2 graves disease 1 29.9 TG TPO
3 thyroiditis 29.9 RET TG TPO
4 endemic goiter 29.8 TG TPO
5 gastrointestinal stromal tumor 29.8 BRAF PTEN TP53
6 thyroid carcinoma, familial medullary 29.8 NKX2-1 RET TG
7 goiter 29.7 NKX2-1 PAX8 TG TPO
8 melanoma 29.4 BRAF MIR19A MIR34C PTEN TP53
9 multinodular goiter 29.4 NKX2-1 PAX8 TG TPO
10 thyroid cancer 29.2 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
11 hashimoto thyroiditis 29.1 BRAF RET TG TPO
12 adenocarcinoma 29.0 BRAF PIK3CA PTEN RET TP53
13 differentiated thyroid carcinoma 28.6 BRAF NKX2-1 PAX8 RET TG TP53
14 papillary carcinoma 28.4 BRAF NKX2-1 PAX8 RET TG TPO
15 nevus of ota 10.4 BRAF TP53
16 atypical follicular adenoma 10.3 TG TP53
17 bladder squamous cell carcinoma 10.3 BRAF TP53
18 hyperplastic polyposis syndrome 10.3 BRAF TP53
19 spitz nevus 10.3 BRAF TP53
20 thyroid cancer, nonmedullary, 1 10.3
21 papillary serous adenocarcinoma 10.3 NKX2-1 TP53
22 chordoid glioma 10.3 NKX2-1 TP53
23 sclerosing liposarcoma 10.3 PAX8 TP53
24 hypertrichosis universalis congenita, ambras type 10.3 TG TP53
25 sarcomatoid renal cell carcinoma 10.2 PAX8 TP53
26 water-clear cell adenoma 10.2 PAX8 TG
27 synchronous bilateral breast carcinoma 10.2 PTEN TP53
28 pleomorphic carcinoma 10.2 NKX2-1 TP53
29 female reproductive endometrioid cancer 10.2 PTEN TP53
30 adult hepatocellular carcinoma 10.2 PIK3CA TP53
31 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
32 malignant spiradenoma 10.2 PIK3CA TP53
33 benign struma ovarii 10.2 RET TG
34 fetal adenoma 10.2 NKX2-1 TG
35 pleomorphic xanthoastrocytoma 10.2 BRAF TP53
36 mature teratoma 10.2 BRAF TG TP53
37 pulmonary blastoma 10.2 NKX2-1 TP53
38 uterine corpus serous adenocarcinoma 10.2 PIK3CA TP53
39 lymphoma 10.2
40 breast squamous cell carcinoma 10.2 PIK3CA TP53
41 colloid adenoma 10.2 NKX2-1 TG TP53
42 uterine body mixed cancer 10.2 PIK3CA TP53
43 anal squamous cell carcinoma 10.2 PIK3CA TP53
44 mixed type thymoma 10.1 PAX8 PTEN
45 thyroid lymphoma 10.1
46 prostate small cell carcinoma 10.1 NKX2-1 PTEN
47 adenoma 10.1 BRAF RET TP53
48 thymus cancer 10.1 NKX2-1 PAX8 TP53
49 erdheim-chester disease 10.1 BRAF PIK3CA
50 giant cell glioblastoma 10.1 BRAF PTEN TP53

Graphical network of the top 20 diseases related to Thyroid Gland Anaplastic Carcinoma:



Diseases related to Thyroid Gland Anaplastic Carcinoma
Sources

Symptoms & Phenotypes for Thyroid Gland Anaplastic Carcinoma

About this section

Human phenotypes related to Thyroid Gland Anaplastic Carcinoma:

60 33 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anaplastic thyroid carcinoma 60 33 obligate (100%) Obligate (100%) HP:0011779
2 broad neck 60 33 hallmark (90%) Very frequent (99-80%) HP:0000475
3 hoarse voice 60 33 hallmark (90%) Very frequent (99-80%) HP:0001609
4 nodular goiter 60 33 hallmark (90%) Very frequent (99-80%) HP:0005994
5 dysphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002015
6 respiratory distress 60 33 frequent (33%) Frequent (79-30%) HP:0002098
7 vocal cord paralysis 60 33 frequent (33%) Frequent (79-30%) HP:0001605
8 pain 60 33 frequent (33%) Frequent (79-30%) HP:0012531
9 neoplasm of the lung 60 33 frequent (33%) Frequent (79-30%) HP:0100526
10 lymphadenopathy 60 33 frequent (33%) Frequent (79-30%) HP:0002716
11 upper airway obstruction 60 33 frequent (33%) Frequent (79-30%) HP:0002781
12 laryngotracheal stenosis 60 33 frequent (33%) Frequent (79-30%) HP:0004894
13 dysphonia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001618
14 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
15 hemoptysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002105
16 cough 60 33 occasional (7.5%) Occasional (29-5%) HP:0012735
17 stridor 60 33 occasional (7.5%) Occasional (29-5%) HP:0010307
18 neoplasm of the skeletal system 60 33 occasional (7.5%) Occasional (29-5%) HP:0010622
19 abnormal muscle morphology 33 occasional (7.5%) HP:0011805
20 tracheoesophageal fistula 60 33 very rare (1%) Very rare (<4-1%) HP:0002575
21 malignant neoplasm of the central nervous system 60 33 very rare (1%) Very rare (<4-1%) HP:0100836
22 dyspnea 60 Occasional (29-5%)
23 goiter 60 Very frequent (99-80%)
24 abnormality of muscle morphology 60 Occasional (29-5%)

MGI Mouse Phenotypes related to Thyroid Gland Anaplastic Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.11 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
2 growth/size/body region MP:0005378 10.09 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
3 homeostasis/metabolism MP:0005376 10.06 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
4 digestive/alimentary MP:0005381 9.95 BRAF NKX2-1 PTEN RET TG TP53
5 limbs/digits/tail MP:0005371 9.91 BRAF PAX8 PTEN RET TG TP53
6 adipose tissue MP:0005375 9.89 BRAF PIK3CA PTEN TG TP53
7 nervous system MP:0003631 9.86 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
8 neoplasm MP:0002006 9.8 BRAF NKX2-1 PIK3CA PTEN RET TP53
9 reproductive system MP:0005389 9.7 BRAF NKX2-1 PAX8 PIK3CA PTEN RET
10 skeleton MP:0005390 9.56 BRAF NKX2-1 PAX8 PIK3CA PTEN TG
11 vision/eye MP:0005391 9.1 BRAF PAX8 PIK3CA PTEN TP53 TPO
Sources

Drugs & Therapeutics for Thyroid Gland Anaplastic Carcinoma

About this section

Drugs for Thyroid Gland Anaplastic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
3 Combretastatin Investigational Phase 2, Phase 3,Phase 3,Phase 1 82855-09-2
4
Fosbretabulin Investigational Phase 2, Phase 3,Phase 3,Phase 1 222030-63-9 5351387
5 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
6 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
7 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
8
leucovorin Approved Phase 2 58-05-9 143 6006
9
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
10
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
11
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
12
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
13
Cisplatin Approved Phase 1, Phase 2,Phase 2 15663-27-1 2767 441203 84093
14
Hydroxyurea Approved Phase 2 127-07-1 3657
15
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
16
Fluorouracil Approved Phase 2 51-21-8 3385
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
19
Iodine Approved, Investigational Phase 2,Not Applicable 7553-56-2 807
20
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
21
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
22
Sodium Citrate Approved, Investigational Phase 2 68-04-2
23
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
24
Tamoxifen Approved Phase 2 10540-29-1 2733526
25
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
26
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
29
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
30
tannic acid Approved Phase 2 1401-55-4
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Ceritinib Approved Phase 2 1032900-25-6
33
nivolumab Approved Phase 2 946414-94-4
34
Ipilimumab Approved Phase 2 477202-00-9
35
Trametinib Approved Phase 2,Early Phase 1 871700-17-3 11707110
36
Lenvatinib Approved, Investigational Phase 2 417716-92-8
37
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
38
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
41
Efatutazone Investigational Phase 1, Phase 2,Phase 2 223132-37-4
42
Doxil Approved June 1999 Phase 2,Phase 1 31703
43 Vitamin B Complex Phase 2
44 Vitamin B9 Phase 2
45 Folate Phase 2
46 Folic Acid Antagonists Phase 2
47 Nucleic Acid Synthesis Inhibitors Phase 2
48 Immunosuppressive Agents Phase 2
49 Antifungal Agents Phase 2
50 Anti-Bacterial Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer Terminated NCT00507429 Phase 2, Phase 3 CA4P;paclitaxel;carboplatin
2 Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Withdrawn NCT01701349 Phase 3 Fosbretabulin + paclitaxel + carboplatin;Placebo + paclitaxel + carboplatin
3 Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
4 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
5 A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed NCT01240590 Phase 1, Phase 2 Crolibulin;Cisplatin
6 A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Completed NCT00603941 Phase 1, Phase 2 CS7017;Paclitaxel
7 Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Completed NCT00060242 Phase 2 fosbretabulin disodium
8 Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer Completed NCT00004089 Phase 2 fluorouracil;hydroxyurea;paclitaxel
9 Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
10 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
11 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
12 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
13 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
14 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
15 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed NCT01524978 Phase 2 cetuximab;vemurafenib;vemurafenib
16 Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer Recruiting NCT03181100 Phase 2 Atezolizumab;Cobimetinib;Nab-paclitaxel;Paclitaxel;Vemurafenib
17 Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Recruiting NCT03565536 Phase 2 Nexavar
18 A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting NCT02244463 Phase 2 MLN0128
19 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Recruiting NCT02688608 Phase 2 Pembrolizumab
20 Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer Recruiting NCT02289144 Phase 2 Ceritinib
21 Nivolumab Plus Ipilimumab in Thyroid Cancer Recruiting NCT03246958 Phase 2 Nivolumab;Ipilimumab
22 Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT01236547 Phase 2 Paclitaxel;Pazopanib Hydrochloride
23 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Active, not recruiting NCT00625846 Phase 2 Pazopanib Hydrochloride
24 Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Active, not recruiting NCT02726503 Phase 2 Lenvatinib
25 Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Active, not recruiting NCT02152137 Phase 2 efatutazone;paclitaxel
26 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting NCT03211117 Phase 2 Docetaxel;Doxorubicin Hydrochloride
27 Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting NCT02404441 Phase 1, Phase 2
28 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
29 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Active, not recruiting NCT02041260 Phase 2 Cabozantinib
30 Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Terminated NCT00115739 Phase 2 Imatinib
31 A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated NCT02657369 Phase 2 Lenvatinib 24 mg
32 Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Terminated NCT00126568 Phase 2 sorafenib tosylate
33 Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer Terminated NCT00804830 Phase 2 Bevacizumab
34 Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer Terminated NCT00077103 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;fosbretabulin disodium
35 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated NCT03002623 Phase 2 CUDC-907
36 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
37 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated NCT02012231 Phase 1, Phase 2 PLX8394
38 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
39 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
40 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
41 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
42 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
43 Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Active, not recruiting NCT03122496 Phase 1 durvalumab;tremelimumab
44 A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers Withdrawn NCT02516774 Phase 1 Adalimumab
45 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
46 Review of Multimodality Management of Anaplastic Thyroid Cancer Completed NCT00280852
47 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
48 interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) Recruiting NCT01774279
49 Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Recruiting NCT03085056 Early Phase 1 Trametinib;Paclitaxel
50 Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 Recruiting NCT03488134

Search NIH Clinical Center for Thyroid Gland Anaplastic Carcinoma

Sources

Genetic Tests for Thyroid Gland Anaplastic Carcinoma

About this section
Sources

Anatomical Context for Thyroid Gland Anaplastic Carcinoma

About this section

MalaCards organs/tissues related to Thyroid Gland Anaplastic Carcinoma:

42
Thyroid, Lymph Node, Endothelial, Brain, Skin, Bone Marrow, Testis
Sources

Publications for Thyroid Gland Anaplastic Carcinoma

About this section

Articles related to Thyroid Gland Anaplastic Carcinoma:

(show top 50) (show all 512)
# Title Authors Year
1
Mediastinal seminoma presenting as a neck mass falsely diagnosed as anaplastic thyroid carcinoma: A case report. ( 30468316 )
2019
2
Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case. ( 30931661 )
2019
3
Metastasis to Stomach in a Patient with Anaplastic Thyroid Carcinoma: A Clinical Challenge. ( 30705249 )
2019
4
Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution. ( 30800638 )
2019
5
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma. ( 30842140 )
2019
6
Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients. ( 30864902 )
2019
7
Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review. ( 30881466 )
2019
8
Case Report: 84-Month Disease-Free Survival after Surgery for Anaplastic Thyroid Carcinoma. ( 30918155 )
2019
9
Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. ( 30924726 )
2019
10
Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. ( 30938231 )
2019
11
Sodium orthovanadate inhibits growth and triggers apoptosis of human anaplastic thyroid carcinoma cells in vitro and in vivo. ( 30944619 )
2019
12
Induction of cell fusion/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. ( 30969451 )
2019
13
Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma. ( 31077090 )
2019
14
Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma. ( 29225265 )
2018
15
Clinico-Pathological Profile of Anaplastic Thyroid Carcinoma in an Endemic Goiter Area. ( 30766820 )
2018
16
Remarkable Presentation: Anaplastic Thyroid Carcinoma Arising from Chronic Hyperthyroidism. ( 29805818 )
2018
17
Anaplastic thyroid carcinoma with rapid thyrotoxicosis - a case report and the literature review. ( 29319130 )
2018
18
Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. ( 29092098 )
2018
19
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. ( 29161986 )
2018
20
Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers. ( 29294167 )
2018
21
Anaplastic thyroid carcinoma: review of treatment protocols. ( 29295821 )
2018
22
miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. ( 29317480 )
2018
23
Anaplastic thyroid carcinoma in Denmark 1996-2012: A national prospective study of 219 patients. ( 29414634 )
2018
24
Fast-growing cervical mass: anaplastic thyroid carcinoma. ( 29437712 )
2018
25
Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. ( 29443941 )
2018
26
Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation. ( 29504819 )
2018
27
Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan. ( 29540641 )
2018
28
Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma. ( 29719407 )
2018
29
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. ( 29742974 )
2018
30
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma. ( 29790111 )
2018
31
New Perspectives Regarding Anaplastic Thyroid Carcinoma Approach Improvement. ( 29886838 )
2018
32
Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study. ( 29923991 )
2018
33
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. ( 29996921 )
2018
34
Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical and molecular single institution study. ( 30075157 )
2018
35
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib. ( 30196299 )
2018
36
Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis. ( 30213925 )
2018
37
Anaplastic thyroid carcinoma mimicking thyroid abscess. ( 30264016 )
2018
38
Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma. ( 30386706 )
2018
39
Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma. ( 30422139 )
2018
40
Anaplastic Thyroid Carcinoma with Gastric Metastasis. ( 30647951 )
2018
41
Anaplastic Thyroid Carcinoma Treated with Lenvatinib. ( 29057760 )
2018
42
Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. ( 28423545 )
2017
43
Comparison of sonographic characteristics of primary thyroid lymphoma and anaplastic thyroid carcinoma. ( 29268549 )
2017
44
Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report. ( 28413394 )
2017
45
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( 28635560 )
2017
46
Inhibition of X-linked inhibitor of apoptosis protein suppresses tumorigenesis and enhances chemosensitivity in anaplastic thyroid carcinoma. ( 29221164 )
2017
47
Imaging of Anaplastic Thyroid Carcinoma. ( 29242360 )
2017
48
ATRA increases iodine uptake and inhibits the proliferation and invasiveness of human anaplastic thyroid carcinoma SW1736 cells: Involvement of β-catenin phosphorylation inhibition. ( 29344218 )
2017
49
Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. ( 27534388 )
2017
50
The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma. ( 27586674 )
2017
Sources

Variations for Thyroid Gland Anaplastic Carcinoma

About this section

ClinVar genetic disease variations for Thyroid Gland Anaplastic Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802

Cosmic variations for Thyroid Gland Anaplastic Carcinoma:

9 (show top 50) (show all 1399)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM7340225 ZNF703 thyroid,NS,carcinoma,anaplastic carcinoma c.1232C>T p.A411V 8:37698133-37698133 0
2 COSM7339394 XPO1 thyroid,NS,carcinoma,anaplastic carcinoma c.1353A>G p.I451M 2:61492946-61492946 0
3 COSM6904745 VHL thyroid,NS,carcinoma,anaplastic carcinoma c.289C>T p.P97S 3:10142136-10142136 0
4 COSM7340191 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.247G>C p.E83Q 21:43095696-43095696 0
5 COSM6969018 U2AF1 thyroid,NS,carcinoma,anaplastic carcinoma c.297G>A p.M99I 21:43095489-43095489 0
6 COSM26483 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1514G>A p.S505N 14:81143572-81143572 0
7 COSM6978154 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1672G>A p.V558M 14:81143730-81143730 0
8 COSM6921338 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1898A>C p.D633A 14:81143956-81143956 0
9 COSM6921339 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1911G>T p.M637I 14:81143969-81143969 0
10 COSM27565 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1789G>C p.V597L 14:81143847-81143847 0
11 COSM26451 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.1703T>C p.I568T 14:81143761-81143761 0
12 COSM26495 TSHR thyroid,NS,carcinoma,anaplastic carcinoma c.842G>C p.S281T 14:81139828-81139828 0
13 COSM6909667 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.5113G>A p.D1705N 16:2088092-2088092 0
14 COSM6909665 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.229G>A p.A77T 16:2053345-2053345 0
15 COSM3706921 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.1439A>G p.Y480C 16:2063049-2063049 0
16 COSM7339930 TSC2 thyroid,NS,carcinoma,anaplastic carcinoma c.793G>T p.G265C 16:2057123-2057123 0
17 COSM6944371 TSC1 thyroid,NS,carcinoma,anaplastic carcinoma c.1444A>G p.I482V 9:132906134-132906134 0
18 COSM7339532 TSC1 thyroid,NS,carcinoma,anaplastic carcinoma c.2293C>T p.Q765* 9:132902703-132902703 0
19 COSM7339616 TRRAP thyroid,NS,carcinoma,anaplastic carcinoma c.3073G>A p.A1025T 7:98927264-98927264 0
20 COSM7339614 TRRAP thyroid,NS,carcinoma,anaplastic carcinoma c.6557G>A p.G2186E 7:98961403-98961403 0
21 COSM6911211 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.288C>G p.I96M 3:189738738-189738738 0
22 COSM6921383 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.503A>G p.N168S 3:189808450-189808450 0
23 COSM6912793 TP63 thyroid,NS,carcinoma,anaplastic carcinoma c.1161G>C p.M387I 3:189869355-189869355 0
24 COSM10728 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.839G>A p.R280K 17:7673781-7673781 0
25 COSM45114 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.702C>A p.Y234* 17:7674261-7674261 0
26 COSM45956 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.783-2A>T p.? 17:7673839-7673839 0
27 COSM10660 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.818G>A p.R273H 17:7673802-7673802 0
28 COSM13584 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.919+1G>T p.? 17:7673700-7673700 0
29 COSM10656 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.742C>T p.R248W 17:7674221-7674221 0
30 COSM10701 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.824G>T p.C275F 17:7673796-7673796 0
31 COSM10943 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.841G>C p.D281H 17:7673779-7673779 0
32 COSM44365 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.607G>T p.V203L 17:7674924-7674924 0
33 COSM10834 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.711G>A p.M237I 17:7674252-7674252 0
34 COSM11392 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.800G>C p.R267P 17:7673820-7673820 0
35 COSM10724 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.839G>C p.R280T 17:7673781-7673781 0
36 COSM45492 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.858A>T p.E286D 17:7673762-7673762 0
37 COSM10659 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.817C>T p.R273C 17:7673803-7673803 0
38 COSM10886 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.310C>T p.Q104* 17:7676059-7676059 0
39 COSM43687 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.641A>G p.H214R 17:7674890-7674890 0
40 COSM44808 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.503A>C p.H168P 17:7675109-7675109 0
41 COSM10648 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.524G>A p.R175H 17:7675088-7675088 0
42 COSM44481 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.313G>T p.G105C 17:7676056-7676056 0
43 COSM10758 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
44 COSM6906 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.672+1G>A p.? 17:7674858-7674858 0
45 COSM10662 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
46 COSM10722 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.853G>A p.E285K 17:7673767-7673767 0
47 COSM44091 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.746G>A p.R249K 17:7674217-7674217 0
48 COSM45672 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.376-2A>G p.? 17:7675238-7675238 0
49 COSM10931 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.751A>C p.I251L 17:7674212-7674212 0
50 COSM10705 TP53 thyroid,NS,carcinoma,anaplastic carcinoma c.586C>T p.R196* 17:7674945-7674945 0

Copy number variations for Thyroid Gland Anaplastic Carcinoma from CNVD:

7 (show all 18)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18562 1 146514610 148102224 Gain Anaplastic thyroid cancer
2 57418 11 63321142 66212707 Gain CCND1 Anaplastic thyroid cancer
3 68082 12 47384342 48639263 Gain Anaplastic thyroid cancer
4 78984 13 61113549 63481793 Loss Anaplastic thyroid cancer
5 99673 16 28082639 28922556 Gain Anaplastic thyroid cancer
6 114238 17 45949240 46466966 Gain Anaplastic thyroid cancer
7 124653 19 11950033 12150103 Gain Anaplastic thyroid cancer
8 128382 19 40542097 41211643 Gain Anaplastic thyroid cancer
9 152529 20 31497814 33184582 Gain Anaplastic thyroid cancer
10 153944 20 41887694 44153298 Gain UBCH10 Anaplastic thyroid cancer
11 161614 22 19538297 19939137 Gain Anaplastic thyroid cancer
12 164302 22 36003989 36444264 Gain Anaplastic thyroid cancer
13 171639 3 170900000 182700000 Copy number PIK3CA Anaplastic thyroid cancer
14 182004 4 132076562 133123563 Loss Anaplastic thyroid cancer
15 188265 4 61317501 66095641 Loss Anaplastic thyroid cancer
16 211600 6 33165527 33494594 Gain Anaplastic thyroid cancer
17 225370 7 45400000 54000000 Amplification EGFR Anaplastic thyroid cancer
18 227803 7 72035816 72259198 Gain Anaplastic thyroid cancer
Sources

Expression for Thyroid Gland Anaplastic Carcinoma

About this section
Search GEO for disease gene expression data for Thyroid Gland Anaplastic Carcinoma.
Sources

Pathways for Thyroid Gland Anaplastic Carcinoma

About this section

Pathways related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Gastric cancer 38
Show member pathways
 12.6 BRAF PIK3CA PTEN TP53
2
Glioma 38
Show member pathways
 12.53 BRAF PIK3CA PTEN TP53
3
Development HGF signaling pathway 23
Show member pathways
 12.53 BRAF PIK3CA PTEN TP53
4
Endometrial cancer 38
Show member pathways
 12.48 BRAF PAX8 PIK3CA PTEN RET TP53
5
Pathways in cancer 38
12.36 BRAF PAX8 PIK3CA PTEN RET TP53
6
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.29 BRAF PIK3CA PTEN TP53
7
DNA Damage Response 1
Show member pathways
 12.07 MIR18A MIR19A PTEN TP53
8
Cellular senescence (KEGG) 38
12 PIK3CA PTEN TP53
9
mTOR Pathway 73
Show member pathways
 11.99 BRAF PIK3CA TP53
10
AKT Signaling Pathway 68
11.98 PIK3CA PTEN TP53
11
Integrated Breast Cancer Pathway 1
11.97 BRAF PTEN TP53
12
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 11.96 BRAF PIK3CA PTEN TP53
13
FoxO signaling pathway 38
Show member pathways
 11.91 BRAF PIK3CA PTEN
14
MAPK Pathway 73
Show member pathways
 11.85 BRAF PIK3CA TP53
15
Sphingolipid signaling pathway 38
11.83 PIK3CA PTEN TP53
16
DNA Damage Response (only ATM dependent) 1
11.8 PIK3CA PTEN TP53
17
Glioblastoma Multiforme 65
11.78 BRAF PTEN TP53
18
Senescence and Autophagy in Cancer 1
11.75 BRAF PTEN TP53
19
Small cell lung cancer 38
11.68 PIK3CA PTEN TP53
20
MicroRNAs in cancer 38
11.64 MIR18A MIR19A MIR30D MIR34C PIK3CA PTEN
21
Parkinsons Disease Pathway 1
11.61 MIR18A MIR19A MIR34C
22
VEGF Pathway (Tocris) 62
Show member pathways
 11.59 BRAF PIK3CA RET
23
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.47 BRAF PAX8 PIK3CA
24
Pathways Affected in Adenoid Cystic Carcinoma 1
11.43 PIK3CA PTEN TP53
25
Copper homeostasis 1
11.23 PIK3CA PTEN TP53
26
Metastatic brain tumor 1
11.09 MIR34C TP53
27
G-protein signaling_K-RAS regulation pathway 23
11.07 BRAF PIK3CA
28
Central carbon metabolism in cancer 38
11.07 PIK3CA PTEN RET TP53
29
Estrogen signaling pathway 1
10.98 BRAF PIK3CA
30
Thyroxine (Thyroid Hormone) Production 1
10.15 TG TPO
Sources

GO Terms for Thyroid Gland Anaplastic Carcinoma

About this section

Biological processes related to Thyroid Gland Anaplastic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.62 BRAF MIR19A PTEN TP53
2 positive regulation of gene expression GO:0010628 9.55 BRAF NKX2-1 PTEN RET TP53
3 negative regulation of epithelial to mesenchymal transition GO:0010719 9.4 NKX2-1 PTEN
4 hormone biosynthetic process GO:0042446 9.37 TG TPO
5 regulation of axon regeneration GO:0048679 9.26 BRAF PTEN
6 negative regulation of sprouting angiogenesis GO:1903671 9.13 MIR18A MIR19A MIR34C
7 thyroid gland development GO:0030878 8.92 BRAF NKX2-1 PAX8 TG
Sources

Sources for Thyroid Gland Anaplastic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....